Jump to main content
Jump to site search

Issue 40, 2013
Previous Article Next Article

Dextran stabilized lanthanum strontium manganese oxide nanoparticles for magnetic resonance imaging

Author affiliations

Abstract

Dextran stabilized ferromagnetic La0.7Sr0.3MnO3 nanoparticles (Dex-LSMO NPs) have been already assessed as a potential hyperthermia agent. Herein we show for the first time by in vivo experimentation that Dex-LSMO NPs can also be used as a new type of contrast agent in magnetic resonance imaging (MRI). Interestingly, Dex-LSMO NPs (average size ≤50 nm) show both positive and negative contrast properties with r1 relaxivity value equal to 6.741 s−1 mg−1 mL and superior r2 value of 778 s−1 mg−1 mL. More importantly, when injected at the site of a tumor (viz. melanoma), Dex-LSMO NPs exhibit strong magnetomotive signals. Elaborate toxicity studies (such as cytotoxicity, haemocompatibility and in vivo toxicity in mice) confirm their biocompatibility and safety up to a dosage of 50 mg Kg−1 for intravenous as well as intraperitoneal administration and 1000 mg Kg−1 in case of subcutaneous route. Our results clearly highlight the utility of Dex-LSMO NPs as a new type of contrast agent for MRI. The possibility of their dual use in diagnostics (MRI) and therapeutics (cancer hyperthermia) can also be envisaged.

Graphical abstract: Dextran stabilized lanthanum strontium manganese oxide nanoparticles for magnetic resonance imaging

Back to tab navigation
Please wait while Download options loads

Supplementary files

Publication details

The article was received on 19 Feb 2013, accepted on 25 Jul 2013 and first published on 08 Aug 2013


Article type: Paper
DOI: 10.1039/C3RA40836A
Citation: RSC Adv., 2013,3, 18489-18497
  •   Request permissions

    Dextran stabilized lanthanum strontium manganese oxide nanoparticles for magnetic resonance imaging

    R. Haghniaz, K. R. Bhayani, R. D. Umrani and K. M. Paknikar, RSC Adv., 2013, 3, 18489
    DOI: 10.1039/C3RA40836A

Search articles by author